Mounjaro: What You Should Know About the New Type 2 Diabetes Medicine
Come May 13th, 2022 a new medicine for Type 2 Diabetes known as Mounjaro (Tirzepatide) became available in the market. It is a first-of-its-class…
This study is looking for participants diagnosed with Type 2 Diabetes currently using long acting insulin as part of their treatment. The study is looking at a once-weekly long acting insulin, compared to a once-daily long acting insulin. Insulin will be provided to all patients throughout the study.
Study participants will receive study-related care and study medication or an approved medication at no charge. You may also receive compensation for travel expenses.
To take part in the study, participants should be:
See if you qualify
CEO and Medical Director
Sub-Investigator
Sub-Investigator
CRC Manager
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Have questions? Call us at (515) 329-6800 or email us at info@iowadiabetes.com.